Covalent inhibitors design and discovery

被引:234
作者
De Cesco, Stephane [1 ]
Kurian, Jerry [1 ]
Dufresne, Caroline [1 ]
Mittermaier, Anthony K. [1 ]
Moitessier, Nicolas [1 ]
机构
[1] McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 0B8, Canada
关键词
Covalent drugs; Drug design; Binding kinetics; Docking; TARGET RESIDENCE TIME; ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE; UDP-N-ACETYLGLUCOSAMINE; DIPEPTIDYL PEPTIDASE-IV; ERBB FAMILY BLOCKER; DRUG DISCOVERY; KINASE INHIBITORS; NATURAL-PRODUCTS; IRREVERSIBLE INHIBITORS; ALKYLATING-AGENTS;
D O I
10.1016/j.ejmech.2017.06.019
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the history of therapeutics, covalent drugs occupy a very distinct category. While representing a significant fraction of the drugs on the. market, very few have been deliberately designed to interact covalently with their biological target. In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors. All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods. The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:96 / 114
页数:19
相关论文
共 126 条
[51]   Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology [J].
Huber, Walter ;
Mueller, Francis .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (31) :3999-4021
[52]   Natural products and drug discovery Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? [J].
Ji, Hong-Fang ;
Li, Xue-Juan ;
Zhang, Hong-Yu .
EMBO REPORTS, 2009, 10 (03) :194-200
[53]   Strategies for discovering and derisking covalent, irreversible enzyme inhibitors [J].
Johnson, Douglas S. ;
Weerapana, Eranthie ;
Cravatt, Benjamin F. .
FUTURE MEDICINAL CHEMISTRY, 2010, 2 (06) :949-964
[54]   Development and validation of a genetic algorithm for flexible docking [J].
Jones, G ;
Willett, P ;
Glen, RC ;
Leach, AR ;
Taylor, R .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (03) :727-748
[55]   Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) [J].
Kim, YB ;
Kopcho, LM ;
Kirby, MS ;
Hamann, LG ;
Weigelt, CA ;
Metzler, WJ ;
Marcinkeviciene, J .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2006, 445 (01) :9-18
[56]   A Chemical Genetic Approach for Covalent Inhibition of Analogue-Sensitive Aurora Kinase [J].
Koch, Andre ;
Rode, Haridas B. ;
Richters, Andre ;
Rauh, Daniel ;
Hauf, Silke .
ACS CHEMICAL BIOLOGY, 2012, 7 (04) :723-731
[57]  
Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO
[58]  
2-8
[59]   Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values [J].
Krippendorff, Ben-Fillippo ;
Neuhaus, Roland ;
Lienau, Philip ;
Reichel, Andreas ;
Huisinga, Wilhelm .
JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (08) :913-923
[60]   Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis [J].
Krishnan, Shyam ;
Miller, Rand M. ;
Tian, Boxue ;
Mullins, R. Dyche ;
Jacobson, Matthew P. ;
Taunton, Jack .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2014, 136 (36) :12624-12630